A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Phase 2Active Not RecruitingNCT07215312

Eli Lilly and Company100 enrolled

Overview

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Diabetes Mellitus, Type 2

Interventions

LY3938577DRUG

Administered SC

DegludecDRUG

Administered SC

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2) Exclusion Criteria: * Have type 1 diabetes

Locations (26)

Tucson Clinical Research Institute

Outcomes

Primary Outcomes

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)

Time frame: Baseline through Week 20

Secondary Outcomes

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Superiority Analysis)

Time frame: Baseline through Week 20

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame: Baseline, Week 20

Pharmacokinetics (PK): Average Concentration of LY3938577

Time frame: Baseline through Week 20

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.